Protagonist Therapeutics (PGF) Price & Analysis

Compare

1 Followers

PGF Stock Chart & Stats

€68.50

-€1.00(-2.69%)

At close: Jan 08 4:00 PM EST

€68.50

-€1.00(-2.69%)

Day’s Range― - ―

52-Week Range€32.20 - €77.50

Previous CloseN/A

Volume0.00

Average Volume (3M)10.00

Market Cap

$4.29B

Enterprise ValueN/A

Total Cash (Recent Filing)$576.12M

Total Debt (Recent Filing)$10.75M

Price to Earnings (P/E)―

Beta0.64

Next Earnings

Mar 18, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.53

Shares Outstanding62,211,320

10 Day Avg. Volume0

30 Day Avg. Volume10

Financial Highlights & Ratios

PEG Ratio-0.02

Price to Book (P/B)3.52

Price to Sales (P/S)5.47

P/FCF Ratio13.00

Enterprise Value/Market Cap0.00

Enterprise Value/Revenue0.00

Enterprise Value/Gross Profit0.00

Enterprise Value/Ebitda0.00

Forecast

1Y Price Target

$77.21

Price Target Upside12.72% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering13

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Drug Efficacy And SafetyIcotrokinra demonstrated statistically higher response rates compared to Sotyktu on both co-primary endpoints and key secondary endpoints.

Financial OutlookPTGX is entitled to significant financial milestones and royalties upon achieving certain clinical and regulatory goals with icotrokinra, indicating potential financial success for the company.

Regulatory ApprovalsData should support FDA and EMA approvals in PsO following partner JNJ's recent NDA and MAA submissions.

Bears Say

Protagonist Therapeutics News

Protagonist Therapeutics price target raised to $81 from $68 at JPMorgan

JPMorgan analyst Brian Cheng raised the firm’s price target on Protagonist Therapeutics (PTGX) to $81 from $68 and...

2d ago

PTGX

Protagonist Therapeutics price target raised to $88 from $72 at Barclays

Barclays raised the firm’s price target on Protagonist Therapeutics (PTGX) to $88 from $72 and keeps an Overweight...

2d ago

PTGX

Protagonist Therapeutics price target raised to $102 from $69 at Citizens JMP

Citizens JMP raised the firm’s price target on Protagonist Therapeutics (PTGX) to $102 from $69 and keeps an...

2d ago

PTGX

Protagonist Therapeutics price target raised to $91 from $74 at Clear Street

Clear Street raised the firm’s price target on Protagonist Therapeutics (PTGX) to $91 from $74 and keeps a...

2d ago

PTGX

Protagonist Therapeutics reports Q3 EPS (62c), consensus (64c)

Reports Q3 revenue $4.71M, consensus $4.14M. “2025 continues to be a highly productive year with significant accomplishments in...

3d ago

PTGX

Protagonist Therapeutics price target raised to $88 from $76 at Truist

Truist raised the firm’s price target on Protagonist Therapeutics (PTGX) to $88 from $76 and keeps a Buy...

12d ago

PTGX

Clear Street sees ‘unmatched commercial promise’ for Protagonist’s icotrokinra

After Protagonist Therapeutics (PTGX) shared extended follow-up data from the Phase 2b ANTHEM-UC study of icotrokinra in ulcerative...

13d ago

JNJ

PTGX

Protagonist Therapeutics announces icotrokinra data in UC, plaque PsO

Protagonist Therapeutics (PTGX) announced new data from two studies of icotrokinra, an investigational targeted oral peptide that precisely...

13d ago

PTGX

3 Stocks with a Flawless 10 Smart Score and Strong Buy Consensus

Amid global market volatility, TipRanks offers valuable tools to guide investors. One of the most powerful is the...

17d ago

IRON

PRAX

Protagonist Therapeutics price target raised to $96 from $72 at Citi

Citi raised the firm’s price target on Protagonist Therapeutics (PTGX) to $96 from $72 and keeps a Buy...

23d ago

PTGX

Protagonist Therapeutics price target raised to $112 from $72 at BMO Capital

BMO Capital raised the firm’s price target on Protagonist Therapeutics (PTGX) to $112 from $72 and keeps an...

27d ago

JNJ

PTGX

Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!

Economic updates, earnings reports, analyst coverage, and more are among the biggest stock market stories on Friday. ...

30d ago

AMD

M&A News: Protagonist Therapeutics Stock (PTGX) is Star of the Show on JNJ Bid Talk

Shares in Protagonist Therapeutics ($PTGX) looked heroic today on a report that it could soon be bought by...

30d ago

JNJ

PTGX

Protagonist Therapeutics Advances Pipeline Amid Financial Loss

Protagonist Therapeutics Inc ( ($PTGX) ) has released its Q3 earnings. Here is a breakdown of the information...

2d ago

PTGX

PGF FAQ

What was Protagonist Therapeutics’s price range in the past 12 months?

Protagonist Therapeutics lowest stock price was €32.20 and its highest was €77.50 in the past 12 months.

What is Protagonist Therapeutics’s market cap?

Protagonist Therapeutics’s market cap is $4.29B.

When is Protagonist Therapeutics’s upcoming earnings report date?

Protagonist Therapeutics’s upcoming earnings report date is Mar 18, 2026 which is in 129 days.

How were Protagonist Therapeutics’s earnings last quarter?

Protagonist Therapeutics released its earnings results on Nov 06, 2025. The company reported -€0.533 earnings per share for the quarter, missing the consensus estimate of -€0.531 by -€0.003.

Is Protagonist Therapeutics overvalued?

According to Wall Street analysts Protagonist Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Protagonist Therapeutics pay dividends?

Protagonist Therapeutics does not currently pay dividends.

What is Protagonist Therapeutics’s EPS estimate?

Protagonist Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Protagonist Therapeutics have?

Protagonist Therapeutics has 62,211,320 shares outstanding.

What happened to Protagonist Therapeutics’s price movement after its last earnings report?

Protagonist Therapeutics reported an EPS of -€0.533 in its last earnings report, missing expectations of -€0.531. Following the earnings report the stock price went up 3.008%.

Which hedge fund is a major shareholder of Protagonist Therapeutics?

Currently, no hedge funds are holding shares in DE:PGF

Protagonist Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

8.61%

Trailing 12-Months

Asset Growth

16.82%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Protagonist Therapeutics

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Protagonist Therapeutics (PGF) Earnings & Revenues

Historic Earnings Reports

PGF Stock 12 Month Forecast

Average Price Target

€77.21

▲(12.72% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"35":"€35","98":"€98","50.75":"€50.8","66.5":"€66.5","82.25":"€82.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":97.16562688,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€97.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":77.21197136,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€77.21</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":62.46361728,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€62.46</span>\n  </div></div>","useHTML":true}}],"tickPositions":[35,50.75,66.5,82.25,98],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,67.5,69.78197129846154,72.06394259692308,74.34591389538461,76.62788519384615,78.9098564923077,81.19182779076924,83.47379908923077,85.75577038769231,88.03774168615385,90.31971298461539,92.60168428307693,94.88365558153848,{"y":97.16562688,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,67.5,68.24707472,68.99414944,69.74122416,70.48829888,71.2353736,71.98244832,72.72952304,73.47659776,74.22367248,74.9707472,75.71782192,76.46489664,{"y":77.21197136,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,67.5,67.11258594461539,66.72517188923077,66.33775783384615,65.95034377846154,65.56292972307692,65.17551566769231,64.7881016123077,64.40068755692307,64.01327350153846,63.62585944615385,63.23844539076923,62.85103133538462,{"y":62.46361728,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":43,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.2,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.6,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.2,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.4,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.2,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.6,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.6,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >